Stifel initiated coverage on Compass Pathways plc, saying, “The Time Is Now for Psychedelics. Compass is a clinical-stage biotechnology company focused on developing psychedelics-based drugs for neuropsychiatric disorders. The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s Spravato
Medical Cannabis News Read more on Benzinga